Q9984 — Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg
Q9984 is a HCPCS Level II code for levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2017 and is not valid on new claims.
This code has been terminated
CMS terminated Q9984 on December 31, 2017. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Non-covered by statute
Excluded from coverage by the Social Security Act itself, not by a policy decision. No documentation and no appeal changes this one — an ABN is the relevant conversation.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q9984
- Long descriptor
- Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg
- Short descriptor
- Kyleena, 19.5 mg
- Added
- July 1, 2017
- Terminated
- December 31, 2017
- BETOS
- P6C
- Pricing indicator
- 00 — Not priced by Part B
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Service not separately priced by Part B — not covered, bundled into another service, or used by Part A only.
Codes adjacent to Q9984
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q9984 is not quite right, the correct code is very often within a few positions of it.
- Q9976Injection, ferric pyrophosphate citrate solution, 0.1 mg of ironterminated
- Q9977Compounded drug, not otherwise classifiedterminated
- Q9978Netupitant 300 mg and palonosetron 0.5 mgterminated
- Q9979Injection, alemtuzumab, 1 mgterminated
- Q9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgterminated
- Q9981Rolapitant, oral, 1 mgterminated
- Q9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
- Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
- Q9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgterminated
- Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mgterminated
- Q9987Pathogen(s) test for plateletsterminated
- Q9988Platelets, pheresis, pathogen-reduced, each unitterminated
- Q9989Ustekinumab, for intravenous injection, 1 mgterminated
- Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
Questions about Q9984
What is HCPCS code Q9984?
Q9984 is a HCPCS Level II code for levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg. It sits in the Temporary Codes section.
Does Medicare cover Q9984?
The CMS HCPCS file marks Q9984 as "Non-covered by statute". Excluded from coverage by the Social Security Act itself, not by a policy decision. No documentation and no appeal changes this one — an ABN is the relevant conversation.
Is Q9984 still valid?
No. Q9984 was terminated on December 31, 2017 and should not be used on new claims.